Skip to content

The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk

The Usefulness of Postprandial Triglyceride for Assessment of Cardiovascular Risk in Healthy People, Impaired Glucose Tolerance and Type 2 Diabetes

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01972542
Enrollment
80
Registered
2013-10-30
Start date
2013-06-30
Completion date
2015-08-31
Last updated
2015-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Prediabetes

Keywords

Postprandial period, triglyceride, Diabetes mellitus, type 2, Prediabetic state

Brief summary

The hypertriglyceridemia at fasting status has been known to be an important risk factor for cardiovascular disease (CVD). Recently, postprandial triglyceride (TG) levels draw an attention as a superior predictor of CVD because of non-fasting state for more than 12 hours and importance of triglyceride-rich lipoprotein. We aim to investigate the relationship of postprandial triglyceride after fat tolerance test and intima-medial thickness and to suggest normal reference of postprandial triglyceride after fat tolerance test. In addition, we evaluate the correlation of postprandial triglyceride and incretin secretion after fat tolerance test Ultimately, we want to estimate clinical importance of postprandial triglyceride in assessment of cardiovascular risk.

Interventions

DIETARY_SUPPLEMENTOral fat tolerance test

Sponsors

Seoul National University Bundang Hospital
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* age : 19 \ 70 yrs * Type 2 diabetes : HbA1c \<10% * Prediabetic state : HbA1c 5.7\ 6.4%

Exclusion criteria

* Type 1 diabetes, secondary diabetes * dipeptidyl peptidase-4 -inhibitor, glucagon-like peptide-1 agonist, thiazolidinediones users * Thyroid disease with abnormal thyroid function test * Liver disease with abnormal liver function test * severe kidney disease * pregnant or lactating women * current smoker * severe obesity

Design outcomes

Primary

MeasureTime frameDescription
Changes of Triglyceride8 hoursBlood sample : drawn by a catheter before the meal and every 1 hour after meal over the 8-hour period

Secondary

MeasureTime frame
Changes of incretin8 hours

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026